Functional Impact of Sequence Alterations Found in BRCA1 Promoter/5'UTR Region in Breast/Ovarian Cancer Families from Upper Silesia, Poland
- PMID: 20222999
- PMCID: PMC3401915
- DOI: 10.1186/1897-4287-4-1-20
Functional Impact of Sequence Alterations Found in BRCA1 Promoter/5'UTR Region in Breast/Ovarian Cancer Families from Upper Silesia, Poland
Abstract
The 5' region of BRCA1 contains multiple regulatory sequences flanking the two alternative promoters alpha and beta and two alternative, non-coding exons, 1a and 1b. Aberrations within the 5' region BRCA1 (encompassing two alternative promoters alpha and beta and exons 1a and 1b) may be associated with an increased risk of breast and ovarian cancer. In this study we screened 150 patients for polymorphism and mutations in this region of BRCA1. All probands came from familial breast and/or ovarian cancer that had been found to be mutation-negative in a previous search for founder mutations in BRCA1 (185delAG, C61G, 4153delA, 5382insC) or BRCA2 (6174delT, 9631delC). In our study we found several sequence alterations within the non-coding region of BRCA1 by using direct DNA sequencing and allele-specific PCR amplification. Three families with a polymorphic deletion in BRCA1 exon 1b (2223delAAAAA, Acc. U37574) were found. Moreover, two linked nucleotide substitutions (2642A>T, 2743T>C, Acc. U37574) in BRCA1 intron 1 were detected in 16 patients. In order to assess the functional significance of these two sequence variants, we constructed a reporter vector encoding firefly luciferase under the transcriptional and translational control of wild type and altered BRCA1 promoter region. The reporter assay was performed using a lung cancer cell line (NCI-H1299) and a breast cancer cell line (MCF7). We have demonstrated that the analysed sequence variants have no functional significance in our experimental system. However, we have found that the BRCA1 promoter has lower relative activity in the breast cancer cell line compared with the lung cancer cell line. Based on the results of our functional experiments we conclude that the polymorphic deletion 2223delAAAAA and two linked substitutions 2642A>T and 2743T>C do not significantly alter BRCA1 expression and are probably not disease-causing mutations.
Figures



Similar articles
-
Selected Aspects of Molecular Diagnostics of Constitutional Alterations in BRCA1 and BRCA2 Genes Associated with Increased Risk of Breast Cancer in the Polish Population.Hered Cancer Clin Pract. 2006 Aug 15;4(3):142-52. doi: 10.1186/1897-4287-4-3-142. Hered Cancer Clin Pract. 2006. PMID: 20223018 Free PMC article.
-
Germline mutations in the BRCA1 gene predisposing to breast and ovarian cancers in Upper Silesia population.Acta Biochim Pol. 2002;49(2):351-6. Acta Biochim Pol. 2002. PMID: 12362976
-
Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.Breast Cancer Res Treat. 2004 Nov;88(2):177-86. doi: 10.1007/s10549-004-0593-8. Breast Cancer Res Treat. 2004. PMID: 15564800
-
BRCA1 founder mutations do not contribute to increased risk of gastric cancer in the Polish population.Hered Cancer Clin Pract. 2016 Jan 15;14:3. doi: 10.1186/s13053-015-0043-0. eCollection 2016. Hered Cancer Clin Pract. 2016. PMID: 26779294 Free PMC article.
-
Assessment of the functional impact of germline BRCA1/2 variants located in non-coding regions in families with breast and/or ovarian cancer predisposition.Breast Cancer Res Treat. 2018 Apr;168(2):311-325. doi: 10.1007/s10549-017-4602-0. Epub 2017 Dec 13. Breast Cancer Res Treat. 2018. PMID: 29236234
Cited by
-
A novel splice site mutation in the noncoding region of BRCA2: implications for Fanconi anemia and familial breast cancer diagnostics.Hum Mutat. 2014 Apr;35(4):442-6. doi: 10.1002/humu.22505. Epub 2014 Feb 15. Hum Mutat. 2014. PMID: 24395671 Free PMC article.
-
Consequences of germline variation disrupting the constitutional translational initiation codon start sites of MLH1 and BRCA2: Use of potential alternative start sites and implications for predicting variant pathogenicity.Mol Carcinog. 2015 Jul;54(7):513-22. doi: 10.1002/mc.22116. Epub 2013 Dec 2. Mol Carcinog. 2015. PMID: 24302565 Free PMC article.
-
GT198 Splice Variants Display Dominant-Negative Activities and Are Induced by Inactivating Mutations.Genes Cancer. 2013 Jan;4(1-2):26-38. doi: 10.1177/1947601913486345. Genes Cancer. 2013. PMID: 23946869 Free PMC article.
References
-
- Baldassarre G, Battista S, Belletti B, Thakur S, Pentimalli F, Trapasso F, Fedele M, Pierantoni G, Croce CM, Fusco A. Negative regulation of BRCA1 gene expression by HMGA1 proteins accounts for the reduced BRCA1 protein levels in sporadic breast carcinoma. Mol Cell Biol. 2003;23:2225–2238. doi: 10.1128/MCB.23.7.2225-2238.2003. - DOI - PMC - PubMed
-
- Baldwin RL, Nemeth E, Tran H, Shvartsman H, Cass I, Narod S, Karlan BY. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res. 2000;60:5329–5333. - PubMed
-
- Brown MA, Xu CF, Nicolai H, Griffiths B, Chambers JA, Black D, Solomon E. The 5' end of the BRCA1 gene lies within a duplicated region of human chromosome 17q21. Oncogene. 1996;12:2507–2513. - PubMed
-
- Brown MA, Lo LJ, Catteau A, Xu CF, Lindeman GJ, Hodgson S, Solomon E. Germline BRCA1 promoter deletions in UK and Australian familial breast cancer patients: Identification of a novel deletion consistent with BRCA1:psiBRCA1 recombination. Hum Mutat. 2002;19:435–442. doi: 10.1002/humu.10055. - DOI - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous